Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Sponsor: Amphastar Pharmaceuticals, Inc.
A PHASE2 clinical study on Asthma and Bronchospasm, this trial is completed. The trial is conducted by Amphastar Pharmaceuticals, Inc. and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jun 2017 — Aug 2017 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amphastar Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .